

News Release

AC BioScience appoints Peter Hug, Ph.D., to the Board of Directors

Lausanne, Switzerland, February 1, 2022 - AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies, announced today that Peter Hug, Ph.D., has been appointed as a new member of its Board of Directors. Dr. Hug is a former Senior Executive of Roche.

Andreas Schläpfer, Chairman of the Board and Co-founder of AC BioScience, said: “We are delighted to welcome Peter to our Board. Peter’s network, long history and experience of pharma partnering and global commercial development will significantly strengthen our efforts in opening business opportunities through the licensing of our products to the pharma industry”.

Dr. Hug is a 35-year veteran of F. Hoffmann-La Roche Ltd. until his retirement in 2018. After having served as Executive Vice President of Roche Pharma Partnering with global responsibilities for licensing, strategic alliances and mergers and acquisitions, he became Head of Pharma Region Europe and afterwards Head of the Pharma Division of EEMEA Region (Eastern Europe, Middle East, Africa). Dr. Hug brings extensive pharmaceutical experience, notably in the development and management of strategic opportunities, the formation of corporate alliances and bringing therapeutic products to market.

Dr. Hug said: “I am excited to join and work with the Board of Directors of AC BioScience at this inflection point when the company starts to prepare for strategic partnerships for its products under clinical validation.”

About AC BioScience

AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor vascular normalization. Its two lead molecules are entering clinical trials in 2022/23: ACB1801 is aiming to potentiate anti PD-1 therapy efficacy through actin dynamic remodeling; clinical trials with mCRC MSI-L/pMMR cancer patients. ACB2003.4 starts with a first-in-man angiogenic cancer therapy in combination with cytotoxic drugs; clinical trials Phase 2 with mPAC patients. For more information, visit www.ac-bioscience.com.

Investors Contact

Christine Evans

christine.evans@ac-bioscience.com